FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112988897> ?p ?o ?g. }

• W2112988897 abstract "Abstract Background Sulphadoxine-pyrimethamine (SP) and chloroquine (CQ) have been used in treatment of falciparum and vivax malaria in Nepal. Recently, resistance to both drugs have necessitated a change towards artemisinin combination therapy (ACT) against Plasmodium falciparum in highly endemic areas. However, SP is still used against P. falciparum infections in low endemic areas while CQ is used in suspected cases in areas with lack of diagnostic facilities. This study examines the prevalence of molecular markers of CQ and SP resistance in P. falciparum and Plasmodium vivax to determine if high levels of in vivo resistance are reflected at molecular level as well. Methods Finger prick blood samples (n = 189) were collected from malaria positive patients from two high endemic districts and analysed for single nucleotide polymorphisms (SNPs) in the resistance related genes of P. falciparum and P. vivax for CQ ( Pfcrt, Pfmdr1, Pvmdr1 ) and SP ( Pfdhfr, Pfdhps, Pvdhfr ), using various PCR-based methods. Results and discussion Positive P. vivax and P. falciparum infections were identified by PCR in 92 and 41 samples respectively. However, some of these were negative in subsequent PCRs. Based on a few P. falciparum samples, the molecular level of CQ resistance in P. falciparum was high since nearly all parasites had the Pfcrt mutant haplotypes CVIET (55%) or SVMNT (42%), though frequency of the Pfmdr1 wild type haplotype was relatively low (35%). Molecular level of SP resistance in P. falciparum was found to be high. The most prevalent Pfdhfr haplotype was double mutant CNRNI (91%), while frequency of Pfdhps double mutant SGEAA and AGEAA were 38% and 33% respectively. Combined, the frequency of quadruple mutations (CNRNI-SGEAA/AGEAA) was 63%. Based on P. vivax samples, low CQ and SP resistance were most likely due to low prevalence of Pvmdr1 Y976F mutation (5%) and absence of triple/quadruple mutations in Pvdhfr . Conclusions Based on the limited number of samples, prevalence of CQ and SP resistance at molecular levels in the population in the study area were determined as high in P. falciparum and low in P. vivax . Therefore, CQ could still be used in the treatment of P. vivax infections, but this remains to be tested in vivo while the change to ACT for P. falciparum seems justified." @default.
• W2112988897 created "2016-06-24" @default.
• W2112988897 creator A5034313016 @default.
• W2112988897 creator A5043443720 @default.
• W2112988897 creator A5044838662 @default.
• W2112988897 creator A5051233081 @default.
• W2112988897 creator A5085522877 @default.
• W2112988897 creator A5088406772 @default.
• W2112988897 creator A5090544775 @default.
• W2112988897 date "2011-04-01" @default.
• W2112988897 modified "2023-10-14" @default.
• W2112988897 title "Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal" @default.
• W2112988897 cites W1594650890 @default.
• W2112988897 cites W1897935955 @default.
• W2112988897 cites W1969146007 @default.
• W2112988897 cites W1977784023 @default.
• W2112988897 cites W1994373940 @default.
• W2112988897 cites W1999748946 @default.
• W2112988897 cites W2004243069 @default.
• W2112988897 cites W2013222714 @default.
• W2112988897 cites W2013267325 @default.
• W2112988897 cites W2014511480 @default.
• W2112988897 cites W2015084644 @default.
• W2112988897 cites W2036079000 @default.
• W2112988897 cites W2036678624 @default.
• W2112988897 cites W2038510509 @default.
• W2112988897 cites W2047232558 @default.
• W2112988897 cites W2047650591 @default.
• W2112988897 cites W2061649602 @default.
• W2112988897 cites W2064855181 @default.
• W2112988897 cites W2076018129 @default.
• W2112988897 cites W2076340545 @default.
• W2112988897 cites W2077298443 @default.
• W2112988897 cites W2079451231 @default.
• W2112988897 cites W2089706810 @default.
• W2112988897 cites W2098322730 @default.
• W2112988897 cites W2099941316 @default.
• W2112988897 cites W2099978923 @default.
• W2112988897 cites W2104536143 @default.
• W2112988897 cites W2124135506 @default.
• W2112988897 cites W2124839325 @default.
• W2112988897 cites W2126901899 @default.
• W2112988897 cites W2131095198 @default.
• W2112988897 cites W2131902613 @default.
• W2112988897 cites W2135192999 @default.
• W2112988897 cites W2135837557 @default.
• W2112988897 cites W2137764200 @default.
• W2112988897 cites W2141986495 @default.
• W2112988897 cites W2150484081 @default.
• W2112988897 cites W2155680390 @default.
• W2112988897 cites W2157571159 @default.
• W2112988897 cites W2157762804 @default.
• W2112988897 cites W2164187904 @default.
• W2112988897 cites W2333050857 @default.
• W2112988897 cites W4318471195 @default.
• W2112988897 doi "https://doi.org/10.1186/1475-2875-10-75" @default.
• W2112988897 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3080351" @default.
• W2112988897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21457533" @default.
• W2112988897 hasPublicationYear "2011" @default.
• W2112988897 type Work @default.
• W2112988897 sameAs 2112988897 @default.
• W2112988897 citedByCount "25" @default.
• W2112988897 countsByYear W21129888972013 @default.
• W2112988897 countsByYear W21129888972014 @default.
• W2112988897 countsByYear W21129888972015 @default.
• W2112988897 countsByYear W21129888972016 @default.
• W2112988897 countsByYear W21129888972017 @default.
• W2112988897 countsByYear W21129888972018 @default.
• W2112988897 countsByYear W21129888972019 @default.
• W2112988897 countsByYear W21129888972020 @default.
• W2112988897 countsByYear W21129888972021 @default.
• W2112988897 countsByYear W21129888972022 @default.
• W2112988897 crossrefType "journal-article" @default.
• W2112988897 hasAuthorship W2112988897A5034313016 @default.
• W2112988897 hasAuthorship W2112988897A5043443720 @default.
• W2112988897 hasAuthorship W2112988897A5044838662 @default.
• W2112988897 hasAuthorship W2112988897A5051233081 @default.
• W2112988897 hasAuthorship W2112988897A5085522877 @default.
• W2112988897 hasAuthorship W2112988897A5088406772 @default.
• W2112988897 hasAuthorship W2112988897A5090544775 @default.
• W2112988897 hasBestOaLocation W21129888971 @default.
• W2112988897 hasConcept C104317684 @default.
• W2112988897 hasConcept C114851261 @default.
• W2112988897 hasConcept C135763542 @default.
• W2112988897 hasConcept C159047783 @default.
• W2112988897 hasConcept C190612196 @default.
• W2112988897 hasConcept C197754878 @default.
• W2112988897 hasConcept C203014093 @default.
• W2112988897 hasConcept C2777035104 @default.
• W2112988897 hasConcept C2777234095 @default.
• W2112988897 hasConcept C2777425658 @default.
• W2112988897 hasConcept C2778048844 @default.
• W2112988897 hasConcept C2778371730 @default.
• W2112988897 hasConcept C2779997623 @default.
• W2112988897 hasConcept C54355233 @default.
• W2112988897 hasConcept C86803240 @default.
• W2112988897 hasConcept C89423630 @default.
• W2112988897 hasConcept C90856448 @default.
• W2112988897 hasConceptScore W2112988897C104317684 @default.
• W2112988897 hasConceptScore W2112988897C114851261 @default.

• next